Get the weekly longevity research breakdown → Join free
GLP-1 peptide injection pen and medical supplies for metabolic health research
Peptides

GLP-1 Peptides: What Researchers Are Saying in 2026

By Mike Hartnett
March 1, 2026 20 Min Read
12 0

Affiliate Disclosure: CoreStacks may earn a commission through affiliate links in this article. This does not influence our editorial independence or how we report on published research and expert commentary. See our Editorial Policy for details.

Table Of Content

The GLP-1 Landscape in 2026: What You Need to Know

The GLP-1 receptor agonist field has evolved from a single-mechanism diabetes drug class into the most active area of metabolic pharmaceutical development in decades. As of February 2026, six major compounds are in various stages of development or approval, spanning single, dual, and triple receptor agonists with weight loss results ranging from 15% to nearly 29% of body weight. Two are FDA-approved. One oral non-peptide candidate could eliminate injections entirely. Clinical trials now extend well beyond obesity into cardiovascular disease, liver disease, kidney protection, and even neurodegeneration.

GLP-1 Compounds at a Glance: The 2026 Pipeline

Compound Developer Mechanism Phase Max Weight Loss (Trials) Key Trial Program FDA Status (Feb 2026)
Semaglutide (Wegovy/Ozempic) Novo Nordisk GLP-1 only Approved ~15% at 68 weeks STEP, SELECT Approved (obesity & T2D)
Tirzepatide (Zepbound/Mounjaro) Eli Lilly GLP-1 + GIP dual agonist Approved ~22.5% at 72 weeks SURMOUNT, SURPASS Approved (obesity & T2D)
Retatrutide Eli Lilly GLP-1 + GIP + Glucagon triple agonist Phase 3 ~28.7% at 68 weeks TRIUMPH Not approved
Survodutide Boehringer Ingelheim GLP-1 + Glucagon dual agonist Phase 3 ~19% at 46 weeks SYNCHRONIZE Not approved
Orforglipron Eli Lilly Oral non-peptide GLP-1 agonist Phase 3 ~14.7% at 36 weeks ATTAIN Not approved
CagriSema Novo Nordisk Semaglutide + Cagrilintide combination Phase 3 ~22.7% at 68 weeks REDEFINE Not approved

Data reflects published trial results and top-line announcements as of February 2026. Weight loss percentages represent highest-dose arms. Individual results in clinical trials varied significantly.

Research-Use-Only Disclaimer: This article discusses pharmaceutical drugs and investigational compounds in the context of published clinical research, expert commentary, and scientific literature. CoreStacks does not provide medical advice, recommend treatments, or suggest human use of any research compound. FDA-approved medications (semaglutide, tirzepatide) require a prescription and medical supervision. Investigational compounds (retatrutide, survodutide, orforglipron, CagriSema) are not approved for any use. Research-grade peptides referenced in this article are sold strictly for in-vitro and laboratory research purposes. See our full Medical Disclaimer.

Get the latest longevity research in your inbox every week.

Join Free →

How GLP-1 Agonists Work: The Receptor Biology Behind the Results

To understand why different GLP-1 drugs produce different outcomes, you need to understand the three receptors involved and what each one does in the body. The progression from semaglutide (one receptor) to tirzepatide (two receptors) to retatrutide (three receptors) is not arbitrary — each additional receptor target adds a distinct metabolic mechanism.

The GLP-1 Receptor: Appetite Suppression and Glucose Control

GLP-1 (glucagon-like peptide-1) is a naturally occurring incretin hormone released by the gut after meals. It binds to GLP-1 receptors in the pancreas, gut, and brain — enhancing glucose-dependent insulin secretion, slowing gastric emptying, and signaling satiety to the hypothalamus. This is the original mechanism, and every compound in the table above activates it.

Semaglutide is the purest expression of this approach. As a GLP-1-only agonist, all of its effects — appetite reduction, glycemic control, and the cardiovascular benefits demonstrated in the SELECT trial — come from this single receptor pathway.

The GIP Receptor: The Metabolic Amplifier

GIP (glucose-dependent insulinotropic polypeptide) is the second incretin hormone. Tirzepatide’s key innovation was adding GIP receptor activation alongside GLP-1. GIP receptors are found in the pancreas, adipose tissue, bone, and brain. GIP receptor activation enhances insulin secretion, influences lipid metabolism and fat storage regulation, and may contribute to central appetite suppression through brain-expressed GIP receptors.

In the SURMOUNT-1 trial, tirzepatide’s dual agonism produced roughly 50% greater weight loss than semaglutide alone — 22.5% vs. approximately 15%. The GIP component appears to amplify the metabolic effects beyond what GLP-1 alone can achieve.

The Glucagon Receptor: Energy Expenditure and Liver Fat

Glucagon is the counter-regulatory hormone to insulin. Adding glucagon receptor activation — as retatrutide and survodutide do — introduces mechanisms that neither GLP-1 nor GIP can provide. The liver is rich in glucagon receptors but has essentially no GLP-1 or GIP receptors. This makes glucagon agonism uniquely effective for hepatic fat metabolism.

According to Coskun et al. in their 2022 Cell Metabolism paper describing retatrutide’s development, glucagon receptor activation drives thermogenesis (increased energy expenditure), hepatic fat oxidation, decreased lipogenesis, and lipolysis. This explains the dramatic liver fat results seen in retatrutide trials, where 93% of participants on the highest dose resolved their fatty liver disease at 48 weeks.

Why Multi-Receptor Agonism Matters

The clinical data tells a clear story of additive benefit:

Receptors Targeted Representative Drug Peak Weight Loss Liver Fat Impact
GLP-1 only Semaglutide ~15% Moderate reduction
GLP-1 + GIP Tirzepatide ~22.5% Significant reduction
GLP-1 + Glucagon Survodutide ~19% Substantial reduction (MASLD focus)
GLP-1 + GIP + Glucagon Retatrutide ~28.7% Near-complete resolution (93%)

Each additional receptor does not simply add more appetite suppression. Rather, it introduces distinct metabolic pathways — insulin sensitization from GIP, energy expenditure and hepatic fat burning from glucagon — that compound with GLP-1’s central appetite effects.

The Current Landscape: What Each Compound Brings to the Table

Semaglutide (Wegovy/Ozempic) — The Established Standard

Semaglutide is the compound that mainstreamed GLP-1 drugs. Developed by Novo Nordisk and approved for obesity (Wegovy, 2021) and type 2 diabetes (Ozempic, 2017), it remains the most widely prescribed GLP-1 agonist and the one with the most extensive safety and outcomes data.

STEP Trials (Obesity): The STEP program demonstrated approximately 14.9% mean weight loss at 68 weeks with the 2.4 mg weekly dose (Wilding et al., NEJM, 2021). These results reshaped the entire obesity treatment paradigm — this was roughly triple what any previous anti-obesity medication had achieved.

SELECT Trial (Cardiovascular Outcomes): Published in NEJM in November 2023, SELECT was a watershed moment. The trial enrolled over 17,600 adults with established cardiovascular disease and overweight/obesity (without diabetes) and demonstrated a 20% reduction in major adverse cardiovascular events (MACE) — heart attack, stroke, and cardiovascular death — with semaglutide 2.4 mg vs. placebo. This was the first definitive proof that a weight loss drug reduces hard cardiovascular endpoints, and it fundamentally changed how the medical establishment views GLP-1 agonists. They are no longer “just” obesity drugs.

Dr. A. Michael Lincoff, the SELECT trial’s lead investigator, stated in the publication that the results established semaglutide as a treatment that reduces cardiovascular risk “irrespective of baseline body weight or the amount of weight lost,” suggesting mechanisms beyond simple weight reduction.

Current Status: Fully approved. The most real-world safety data of any GLP-1. The cardiovascular outcomes data from SELECT gives semaglutide a major evidence advantage over newer competitors that lack outcomes trials.

Tirzepatide (Zepbound/Mounjaro) — The Dual-Agonist Leader

Tirzepatide, Eli Lilly’s GLP-1/GIP dual agonist, raised the ceiling on pharmacological weight loss when it was approved for obesity (Zepbound) in 2023 and type 2 diabetes (Mounjaro) in 2022.

SURMOUNT Trials (Obesity): SURMOUNT-1, published by Jastreboff et al. in NEJM (2022), reported 22.5% mean weight loss at 72 weeks with the 15 mg dose. More than one-third of participants on the highest dose lost 25% or more of their body weight. The SURMOUNT-2 trial in patients with T2D and obesity showed up to 15.7% weight loss.

SURPASS Trials (Type 2 Diabetes): The SURPASS program demonstrated superior A1C reduction compared to all active comparators, including insulin. SURPASS-2 showed tirzepatide reducing A1C by up to 2.46 percentage points — with weight loss of up to 13.1%.

Current Status: Fully approved. The highest approved weight loss of any obesity medication. However, tirzepatide lacks the cardiovascular outcomes trial data that semaglutide has from SELECT. Eli Lilly’s SURPASS-CVOT trial is ongoing and expected to report in 2027.

For a deeper look at tirzepatide’s receptor mechanism, see our Retatrutide research article, which compares the dual and triple agonist approaches.

Retatrutide — The Triple-Agonist Pushing the Ceiling

Retatrutide (LY3437943) is Eli Lilly’s investigational triple-receptor agonist targeting GLP-1, GIP, and glucagon simultaneously. It has produced the highest weight loss figures of any compound in clinical development.

Phase 2 Results (Jastreboff et al., NEJM 2023): At 48 weeks, the 12 mg dose achieved 24.2% mean weight loss, with 83% of participants losing at least 15% of body weight. Notably, this exceeded tirzepatide’s Phase 3 peak — and the retatrutide trial was only 48 weeks compared to tirzepatide’s 72.

TRIUMPH-4 (First Phase 3 Readout, December 2025): Eli Lilly announced the first Phase 3 results on December 11, 2025. In adults with obesity and knee osteoarthritis, the 12 mg dose achieved 28.7% mean weight loss at 68 weeks. That is approximately 71 pounds for the average participant. WOMAC pain scores improved by up to 75.8%, and more than one in eight retatrutide-treated patients became completely free from knee pain.

Liver Fat Data (Sanyal et al., Nature Medicine 2024): The Phase 2a liver substudy, led by Dr. Arun Sanyal of Virginia Commonwealth University, showed that 93% of participants on the 12 mg dose resolved their fatty liver disease (achieved less than 5% liver fat) at 48 weeks. Dr. Sanyal noted that the glucagon component “raises the possibility that in the early stages of liver disease, it is possible to ‘de-fat’ the liver.”

Safety Signal — Dysesthesia: TRIUMPH-4 reported a new safety signal: dysesthesia (abnormal skin sensation such as tingling, numbness, or burning), occurring at rates higher than in earlier phases. This requires monitoring in subsequent TRIUMPH readouts and is being closely tracked by researchers.

What’s Next: The remaining TRIUMPH readouts — including TRIUMPH-1 (obesity without diabetes, 80 weeks) and TRIUMPH-2 (type 2 diabetes) — are expected in early-to-mid 2026. Analysts project the longer TRIUMPH-1 trial could show weight loss exceeding 30%.

We have a dedicated deep-dive on this compound: Retatrutide: What the Research Says About Eli Lilly’s Triple-Agonist Peptide.

Survodutide — The Liver Disease Specialist

Survodutide (BI 456906), developed by Boehringer Ingelheim and Zealand Pharma, is a GLP-1/glucagon dual agonist with a distinct clinical focus on metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH).

Phase 2 Results: In the Phase 2 trial published by Sanyal et al. in NEJM (2024), survodutide at the highest dose achieved up to 19% weight loss at 46 weeks. More importantly for its positioning, 83% of participants achieved MASH resolution without worsening of fibrosis, and 52% achieved fibrosis improvement — both significantly above placebo.

SYNCHRONIZE Program: Survodutide is now in Phase 3 with the SYNCHRONIZE trial program, targeting MASH as its primary indication. This positions it differently from the broader obesity-focused programs of tirzepatide and retatrutide, though its weight loss is also substantial.

What Makes It Different: By pairing GLP-1 with glucagon (instead of GIP), survodutide takes a liver-first approach. The glucagon component drives hepatic fat reduction while the GLP-1 component provides appetite suppression and glycemic control. It lacks the GIP component that enhances the weight loss ceiling of tirzepatide and retatrutide.

Orforglipron — The Oral Game-Changer

Orforglipron (LY3502970) is Eli Lilly’s oral, non-peptide GLP-1 receptor agonist. Unlike every other compound on this list, it is not a peptide — it is a small molecule that can be taken as a daily pill rather than a weekly injection. If approved, it would be the first oral GLP-1 medication for obesity.

Phase 2 Results (Wharton et al., NEJM 2023): At 36 weeks, the highest dose achieved 14.7% mean weight loss. While this is lower than injectable competitors, the oral route of administration could dramatically expand the addressable patient population.

ATTAIN Program: Phase 3 trials are underway. The ATTAIN-1 trial (obesity without diabetes) completed enrollment in 2024. Readouts are expected in 2026. ATTAIN-4, a cardiovascular outcomes trial, is also in progress, potentially giving orforglipron outcomes data early in its lifecycle.

Why It Matters: Dr. Ania Jastreboff, who led the Phase 2 trial, has emphasized that injection aversion is a real barrier to treatment. An effective oral option removes a major hurdle. However, the weight loss magnitude will need to be competitive — and at 14.7% at only 36 weeks, the full Phase 3 data at longer durations may tell a different story.

CagriSema — Novo Nordisk’s Combination Bet

CagriSema combines semaglutide 2.4 mg with cagrilintide, a long-acting amylin analog. Amylin is a pancreatic hormone co-secreted with insulin that promotes satiety and slows gastric emptying through pathways distinct from GLP-1.

REDEFINE-1 Results (2024): CagriSema achieved approximately 22.7% mean weight loss at 68 weeks, compared to 15.5% for semaglutide alone in the same trial. However, the results fell slightly short of the 25%+ that some analysts had anticipated, and the stock market reacted accordingly.

Current Status: Phase 3 ongoing. CagriSema is Novo Nordisk’s primary answer to tirzepatide’s weight loss superiority and the threat from retatrutide. The amylin mechanism adds a genuinely distinct pathway that targets the area postrema and other brainstem regions.

What Experts Are Saying

Peter Attia on GLP-1s: “Potentially Transformative” — With Caveats

Dr. Peter Attia has discussed GLP-1 receptor agonists extensively on The Drive podcast and in his clinical practice commentary. His position has evolved from cautious interest to what he describes as recognition of their transformative potential for metabolic health.

Attia’s key points, drawn from multiple podcast episodes and his newsletter:

On the metabolic benefits: Attia has characterized GLP-1 agonists as potentially the most significant pharmacological development for metabolic disease in his career. He views the cardiovascular outcomes data from SELECT as particularly compelling, noting that a 20% reduction in MACE in patients with obesity represents a paradigm shift.

On muscle preservation — his primary concern: Attia has repeatedly emphasized that weight loss from GLP-1 agonists is not purely fat loss. A significant proportion — he has cited figures in the range of 25-40% of total weight lost — can be lean mass, including muscle. For patients in their 50s, 60s, and beyond, losing muscle mass carries its own mortality risk. Attia has argued that GLP-1 prescriptions should be paired with resistance training protocols and adequate protein intake (he has discussed targets of 1.6-2.2 g/kg/day in this context) and that clinicians who prescribe GLP-1s without addressing muscle preservation are doing their patients a disservice.

On long-term use: Attia has noted the emerging data showing that most patients regain weight after discontinuing GLP-1 agonists. This suggests they may need to be chronic medications for many patients — raising questions about decades-long safety profiles that do not yet exist in the data.

Andrew Huberman on GLP-1 Mechanisms: The Brain-Gut Connection

Dr. Andrew Huberman covered GLP-1 agonist mechanisms on the Huberman Lab podcast, bringing his neuroscience lens to the conversation. His discussion focused less on specific drugs and more on the underlying biology.

Huberman’s key points:

On appetite and reward pathways: Huberman has explained how GLP-1 agonists do not simply reduce hunger — they alter the reward value of food by acting on dopaminergic circuits. He has discussed research showing that semaglutide users report reduced cravings not only for food but for alcohol and other addictive substances, suggesting effects on reward pathways that extend beyond appetite.

On the gut-brain axis: Huberman discussed how native GLP-1 is released from L-cells in the gut and acts both locally (slowing gastric emptying) and centrally (via vagal afferents and direct brain penetration). He emphasized that the synthetic versions used in drugs like semaglutide are far more potent and longer-lasting than the natural hormone, which has a half-life of only 2-3 minutes.

On practical considerations: Huberman has discussed the importance of maintaining exercise routines while on GLP-1 agonists, echoing Attia’s muscle preservation concerns from a neuroscience perspective — noting that the motivation to exercise may itself be altered by changes in dopaminergic signaling.

For more on Huberman’s approach to health optimization, see our complete breakdown of Andrew Huberman’s Supplement Stack 2026.

What Trial Investigators Are Saying

The researchers running these trials are notably bullish — within appropriate scientific language.

Dr. Ania Jastreboff (Yale), who has led Phase 2 trials for both tirzepatide and retatrutide, has described the triple-agonist approach as opening “new frontiers in metabolic medicine” and emphasized the dose-dependent weight loss responses suggesting that the ceiling has not yet been reached.

Dr. Arun Sanyal (VCU), whose liver fat research with retatrutide showed near-complete MASLD resolution, has called the results “unprecedented” and noted the implications for preventing progression to cirrhosis and liver cancer.

Dr. A. Michael Lincoff (Cleveland Clinic), who led the SELECT cardiovascular outcomes trial, has emphasized that the cardiovascular benefits of semaglutide appear to extend beyond what can be explained by weight loss alone — pointing to direct anti-inflammatory and anti-atherosclerotic mechanisms.

My Experience With GLP-1 Peptides

I’ve been in the GLP-1 space for over a year personally — tirzepatide, retatrutide, cagrilintide, and MOTS-c. I got into it for a combination of reasons: body composition, metabolic health, and honestly just curiosity about the longevity angle. The research on GLP-1 receptor agonists goes way beyond weight loss at this point.

What I can tell you from personal experience is that the body composition changes are legit. I maintained a three-day-a-week lifting program the entire time and actually put on muscle while losing fat. My bloodwork markers improved. Side effects were minimal — some mild GI stuff early on with each new compound, but nothing that lasted.

The biggest thing I’ve learned going through multiple compounds is that individual response varies massively. My wife and I were on tirzepatide at the same time — she had zero issues, I got elevated heart rate at night. I switched to retatrutide and the problem disappeared. Same class of drug, completely different experience. That’s why I’m skeptical of anyone who tells you one compound is definitively better than another. Your body is the variable they can’t account for.

I sourced through both clinics and research suppliers at different points. Both have tradeoffs — clinics give you medical oversight but cost significantly more. Research suppliers are cheaper but you’re on your own for dosing and monitoring. I’d recommend bloodwork either way, regardless of how you source.

I cover the latest GLP-1 research, new compounds entering trials, and practical sourcing info in The CoreStacks Longevity Report — free, weekly, no fluff.

Beyond Weight Loss: The Expanding Research Frontier

The most significant shift in GLP-1 research over the past 18 months has been the expansion of clinical investigation into conditions that have nothing to do with weight management. Researchers are increasingly treating the metabolic effects as a foundation for broader therapeutic applications.

Cardiovascular Disease

The SELECT trial established that semaglutide reduces MACE by 20% in patients with obesity and established cardiovascular disease. But the research has not stopped there. Post-hoc analyses have shown reductions in heart failure hospitalization, and Eli Lilly’s SURPASS-CVOT trial will test whether tirzepatide delivers similar cardiovascular protection. The mechanistic hypothesis — that GLP-1 agonists reduce systemic inflammation, improve endothelial function, and reduce atherogenic lipid profiles — is supported by biomarker data from multiple trials. If the dual and triple agonists show cardiovascular benefits comparable to or exceeding semaglutide’s, the implications for cardiology practice would be substantial.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/MASH)

Liver disease may be the most transformative application beyond weight loss. Retatrutide’s Phase 2a liver substudy showed 93% MASLD resolution at the highest dose. Survodutide’s Phase 2 trial showed 83% MASH resolution. These results are in a disease state where, until recently, no approved drug treatment existed (resmetirom/Rezdiffra received limited approval in 2024).

The glucagon receptor component appears to be critical here. Compounds with glucagon agonism (retatrutide, survodutide) consistently show more dramatic liver fat reduction than GLP-1-only or GLP-1/GIP drugs. This aligns with the biology — the liver is rich in glucagon receptors and has minimal GLP-1 or GIP receptor expression.

Chronic Kidney Disease

Semaglutide’s FLOW trial, published in 2024, showed a 24% reduction in the risk of major kidney disease events in patients with type 2 diabetes and CKD. This was the first GLP-1 agonist trial with a primary kidney endpoint, and it was stopped early for efficacy. The data suggests renoprotective effects that add another dimension to the clinical value proposition.

Alzheimer’s Disease and Neurodegeneration

Multiple observational studies have reported associations between GLP-1 agonist use and reduced Alzheimer’s disease incidence. GLP-1 receptors are expressed in the hippocampus and other brain regions involved in memory and cognition. Several randomized controlled trials are now underway testing semaglutide in early-stage Alzheimer’s disease (the EVOKE and EVOKE+ trials), with results expected in 2026-2027. While it is far too early to draw conclusions, the biological plausibility (anti-inflammatory effects, improved insulin signaling in the brain, reduced neuronal stress) has attracted serious research attention.

Addiction and Behavioral Health

Perhaps the most unexpected research direction involves addiction. Multiple case reports, retrospective analyses, and now prospective trials are examining whether GLP-1 agonists reduce alcohol consumption, nicotine cravings, and other addictive behaviors. The mechanistic theory centers on GLP-1’s effects on mesolimbic dopamine pathways — the same reward circuits hijacked by addictive substances. As Huberman has discussed on his podcast, this points to a broader role for GLP-1 signaling in reward processing, not just appetite.

The Research Peptide Market: An Important Distinction

With interest in GLP-1 compounds at an all-time high, it is critical to understand the distinction between FDA-approved pharmaceutical medications and research-grade peptides. These are fundamentally different products with different regulatory frameworks, manufacturing standards, and intended use cases.

FDA-Approved Pharmaceuticals

Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are prescription medications manufactured under FDA-regulated Good Manufacturing Practice (GMP) conditions. They are prescribed by physicians, dispensed by pharmacies, and supported by extensive clinical trial safety data. They are intended for human use under medical supervision.

Research-Grade Peptides

Research-grade GLP-1 peptides are synthesized for in-vitro research and laboratory applications. They are sold by research chemical suppliers and are not manufactured under pharmaceutical GMP conditions. They lack the clinical safety data, purity guarantees, and regulatory oversight of pharmaceutical products. They are legally sold as research chemicals, not medications.

The key differences include:

Factor Pharmaceutical GLP-1 Drugs Research-Grade GLP-1 Peptides
Regulation FDA-approved, GMP manufacturing Research use only, variable standards
Purity verification Pharmaceutical-grade QC Third-party COA (if available)
Safety data Thousands-patient clinical trials No clinical safety data
Intended use Human therapeutic use, prescribed In-vitro/laboratory research only
Availability Prescription required Research supplier catalog
Sterility Pharmaceutical sterility standards Variable by supplier

CoreStacks covers both the pharmaceutical developments and the research peptide landscape because both are relevant to the broader conversation about GLP-1 science. However, we strongly emphasize: FDA-approved medications with established safety profiles, prescribed by a physician, represent an entirely different category than research chemicals.

For researchers evaluating peptide supplier quality, see our Best Research Peptide Suppliers 2026 guide, which covers third-party testing standards, COA verification, and supplier evaluation criteria.

Check Peptide Sciences availability

Check Swiss Chems availability

What’s Changed Recently

December 11, 2025: Eli Lilly announces TRIUMPH-4 results — retatrutide achieves 28.7% weight loss at 68 weeks, the highest figure reported in any Phase 3 obesity trial. Dysesthesia emerges as a new safety signal requiring further monitoring.

Late 2024: Semaglutide FLOW trial (kidney outcomes) published, showing 24% risk reduction in major kidney disease events. Trial stopped early for efficacy.

Late 2024: CagriSema REDEFINE-1 results reported at 22.7% weight loss — solid but below analyst expectations of 25%+.

Mid 2024: Retatrutide liver fat substudy (Sanyal et al.) published in Nature Medicine, showing 93% MASLD resolution at highest dose.

Early 2024: Survodutide Phase 2 MASH results published, showing 83% resolution rate. Phase 3 SYNCHRONIZE program initiated.

November 2023: SELECT cardiovascular outcomes trial published, establishing semaglutide’s 20% MACE reduction in the non-diabetic obesity population.

Expected 2026: TRIUMPH-1 and TRIUMPH-2 readouts (retatrutide Phase 3), ATTAIN readouts (orforglipron Phase 3), continued enrollment in Alzheimer’s trials (EVOKE/EVOKE+).

Disclaimers

Research Peptide Disclaimer: Research peptides discussed in this article are referenced strictly in the context of published scientific research and in-vitro/laboratory applications. CoreStacks does not recommend, endorse, or provide guidance on human use of any research compound. We do not provide reconstitution instructions, dosing protocols, or administration guidance for research peptides. When we link to peptide suppliers, those products are sold for research and laboratory use only. Any reference to biological effects is drawn from published, peer-reviewed studies and is provided for scientific context, not as a recommendation for personal use. Peptide regulation varies by jurisdiction; it is your responsibility to understand and comply with applicable laws.

Medical Disclaimer: Nothing in this article constitutes medical advice, diagnosis, or treatment recommendations. When we report that a researcher or expert has discussed a specific compound, protocol, or clinical finding, we are reporting their publicly shared views — not prescribing. GLP-1 agonist medications are prescription drugs with real side effects and contraindications that require physician oversight. Consult a qualified healthcare professional before making any decisions about pharmaceutical treatments. See our full Medical Disclaimer.

Frequently Asked Questions

What is the difference between GLP-1 agonists and GLP-1 “peptides”?

In pharmaceutical contexts, GLP-1 agonists refer to FDA-approved medications like semaglutide and tirzepatide — manufactured under strict pharmaceutical conditions, supported by clinical trials, and prescribed by physicians. The term “GLP-1 peptides” is more commonly used in the research chemical market to refer to synthetic peptides sold for laboratory and in-vitro research. While the active molecules may be structurally related, the manufacturing standards, purity verification, regulatory status, and intended use are fundamentally different.

Which GLP-1 drug produces the most weight loss?

Based on published clinical trial data as of February 2026, retatrutide has demonstrated the highest peak weight loss at 28.7% of body weight at 68 weeks in the TRIUMPH-4 Phase 3 trial. However, retatrutide is not yet FDA-approved. Among approved drugs, tirzepatide (Zepbound) holds the record at approximately 22.5% in the SURMOUNT-1 trial. It is important to note that these are mean (average) figures — individual results varied considerably in every trial.

Are GLP-1 agonists safe long-term?

Semaglutide has the longest track record, with the SELECT trial following over 17,600 patients for a mean of 39.8 months. That trial’s safety profile was generally consistent with earlier data. However, truly long-term data (10+ years) does not yet exist for any GLP-1 agonist. Known side effects across the class include nausea, vomiting, diarrhea (especially during dose escalation), and less commonly pancreatitis and gallbladder events. Peter Attia has publicly raised the question of what decades-long use looks like, particularly regarding lean mass preservation. This is an active area of clinical follow-up.

Will retatrutide be approved in 2026?

Based on the timeline of the TRIUMPH Phase 3 program, full FDA approval in 2026 is unlikely. The remaining TRIUMPH readouts are expected throughout 2026, and the FDA review process typically requires 10-12 months after a complete submission. Most industry analysts project potential approval in late 2027 at the earliest, assuming positive Phase 3 data across the program.

What about the oral GLP-1 (orforglipron)?

Orforglipron is a non-peptide, small-molecule GLP-1 agonist taken as a daily oral tablet. Its Phase 2 results showed approximately 14.7% weight loss at 36 weeks — lower than injectable competitors but potentially transformative if it can eliminate the injection barrier for millions of patients. Phase 3 results from the ATTAIN program are expected in 2026. The question is whether the convenience advantage can offset a potentially lower efficacy ceiling.

Do GLP-1 drugs only work for weight loss?

No. The clinical research has expanded dramatically beyond weight loss. Semaglutide has demonstrated a 20% reduction in major cardiovascular events (SELECT trial) and a 24% reduction in major kidney disease events (FLOW trial). Retatrutide and survodutide show extraordinary results in liver fat reduction. Trials are ongoing for Alzheimer’s disease, addiction, and obstructive sleep apnea. The GLP-1 receptor is expressed throughout the body — in the brain, heart, kidneys, liver, and vasculature — suggesting these drugs affect multiple organ systems simultaneously.

Is there a difference between Ozempic and Wegovy?

Both contain semaglutide made by Novo Nordisk. The difference is the indication and dose. Ozempic is approved for type 2 diabetes at doses up to 2 mg/week. Wegovy is approved for weight management at 2.4 mg/week. They are the same molecule at different doses, approved through different regulatory pathways for different conditions.

What is muscle loss risk with GLP-1 drugs, and can it be mitigated?

Clinical trials show that approximately 25-40% of weight lost on GLP-1 agonists can be lean mass (including muscle), though the ratio varies by compound and individual. Peter Attia has been particularly vocal about this concern, arguing that resistance training and high protein intake (1.6-2.2 g/kg/day) should be standard alongside GLP-1 prescriptions. Some researchers are investigating whether combining GLP-1 agonists with myostatin inhibitors or other muscle-sparing agents could address this issue. For patients over 50, preserving muscle mass is not cosmetic — sarcopenia (age-related muscle loss) is independently associated with increased mortality.

Keep Reading

Sources

  1. Wilding, J.P.H. et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021. DOI: 10.1056/NEJMoa2032183
  2. Jastreboff, A.M. et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022. DOI: 10.1056/NEJMoa2206038
  3. Jastreboff, A.M. et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine, 2023. DOI: 10.1056/NEJMoa2301972
  4. Rosenstock, J. et al. “Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Comparator-Controlled, Parallel-Group, Phase 2 Trial.” The Lancet, 2023. DOI: 10.1016/S0140-6736(23)01053-X01053-X)
  5. Sanyal, A.J. et al. “Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease.” Nature Medicine, 2024. DOI: 10.1038/s41591-024-03018-2
  6. Lincoff, A.M. et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine, 2023. DOI: 10.1056/NEJMoa2307563
  7. Coskun, T. et al. “LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss.” Cell Metabolism, 2022. DOI: 10.1016/j.cmet.2022.07.013
  8. Wharton, S. et al. “Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.” New England Journal of Medicine, 2023. DOI: 10.1056/NEJMoa2302392
  9. Perkovic, V. et al. “Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.” New England Journal of Medicine, 2024. DOI: 10.1056/NEJMoa2403347
  10. Sanyal, A.J. et al. “Survodutide for Steatohepatitis.” New England Journal of Medicine, 2024.
  11. Eli Lilly and Company. “TRIUMPH-4 Phase 3 Top-Line Results.” Press release, December 11, 2025.
  12. Novo Nordisk. “CagriSema REDEFINE-1 Phase 3 Results.” Press release, 2024.

This article is regularly updated as new trial data and expert commentary become available. Last reviewed: February 27, 2026.

For weekly updates on GLP-1 research, expert protocol changes, and longevity science news, subscribe to the CoreStacks newsletter.

Get the latest longevity research in your inbox every week.

Join Free →

Related Reading on CoreStacks:

If you made it this far, you'll like the newsletter. One email per week — the research that matters, the supplements that work, the ones that don't. Free.

Join the Newsletter →

Share Article

Author

Mike Hartnett

Mike tracks what leading longevity researchers actually take, test, and recommend. CoreStacks reports on expert protocols and published research to help you make informed decisions about your health.

Follow Me
Other Articles

Related Posts

Scroll

Our site uses cookies. By using this site, you agree to the Privacy Policy

Accept